{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:31:03Z","timestamp":1793316663858,"version":"4.5.0"},"reference-count":79,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"SIRG CityU Strategic Interdisciplinary Research Grant","award":["7020093"],"award-info":[{"award-number":["7020093"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,2,26]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Drug-resistant tuberculosis (DR-TB) presents a significant global obstacle to TB control efforts, necessitating improved intervention strategies. The introduction of potent drugs, such as bedaquiline (Bdq), has led to the development of shorter treatment regimens. This systematic review and meta-analysis aimed to examine the impact of these regimens, synthesising data from recent clinical trials and observational studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched multiple databases, including Medline and Scopus, for studies published from 2012 to February 2024. Eligible studies included clinical trials and cohort studies involving adults diagnosed with DR-TB treated with Bdq-based all-oral regimens lasting up to 12 months. Primary outcomes were treatment success rate (TSR) and incidence of serious adverse events (SAEs). We also compared efficacy and safety with longer oral or injectable regimens in control groups. Meta-analyses were conducted to pool event rates and risk ratios (RRs). Subgroup analyses and meta-regression were performed to identify potential sources of heterogeneity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 12 studies involving 1902 DR-TB patients across 11 countries were analysed. The pooled TSR was 83% (95% CI 77% to 89%), with mortality, treatment failure and loss to follow-up (LTFU) rates of 5% (3\u20138), 4% (2\u20136) and 4% (2\u20136), respectively. Subgroup analyses showed no significant differences in TSR by DR-TB type or HIV status. The incidence rate of SAE was 19% (13\u201324), with prolonged corrected QT interval (QTc) in 5% (2\u20138) of cases. Compared with the control regimens, all-oral Bdq-based shorter regimens significantly improved treatment success (RR 1.22, 1.04\u20131.43) but reduced mortality (RR 0.73, 0.69\u20130.99), treatment failure (RR 0.33, 0.32\u20130.62) and QTc prolongation (RR 0.39, 0.21\u20130.73).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>All-oral Bdq-based shorter regimens have improved treatment outcomes and significantly advanced DR-TB management. We urge policymakers, clinicians and stakeholders to expand access to and expedite the implementation of these regimens.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgh-2024-018220","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T16:26:17Z","timestamp":1744043177000},"page":"e018220","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of all-oral bedaquiline-based shorter regimens in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4926-0685","authenticated-orcid":false,"given":"Ginenus","family":"Fekadu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China"},{"name":"School of Pharmacy, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7936-9024","authenticated-orcid":false,"given":"Tadesse","family":"Tolossa","sequence":"additional","affiliation":[{"name":"Deakin Health Economics, School of Health and Social Development, Institute for Health Transformation, Deakin University, Geelong 3220, Victoria, Australia"},{"name":"School of Public Health, Institutes of Health Sciences, Wollega University, Nekemte, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firomsa","family":"Bekele","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getahun","family":"Fetensa","sequence":"additional","affiliation":[{"name":"School of Nursing and Midwifery, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia"},{"name":"Department of Health, Behavior, and Society, Faculty of Public Health, Institute of Health, Jimma University, Jimma, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinka","family":"Dugassa","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebisa","family":"Turi","sequence":"additional","affiliation":[{"name":"Deakin Health Economics, School of Health and Social Development, Institute for Health Transformation, Deakin University, Geelong 3220, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesfaye Regassa","family":"Feyissa","sequence":"additional","affiliation":[{"name":"Deakin Rural Health, School of Medicine, Faculty of Health, Deakin University, Warrnambool, Victoria, Australia"},{"name":"Geohealth Laboratory, Dasman Diabetes Institute, Kuwait City 15462, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-8794","authenticated-orcid":false,"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, The University of Utah College of Pharmacy, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6201-4318","authenticated-orcid":false,"given":"Lianping","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Public Health, Sun Yat-Sen University, Guangzhou, China"},{"name":"Institute for Global Health and Development, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanquan","family":"Chen","sequence":"additional","affiliation":[{"name":"International Centre for Evidence in Disability, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8846-7515","authenticated-orcid":false,"given":"Wai-Kit","family":"Ming","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China"},{"name":"Institute of Global Governance and Innovation for a Shared Future, City University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"2025072913113118000_10.4.e018220.1","unstructured":"World Health Organization . Global tuberculosis report 2024. 2024. Available: https:\/\/iris.who.int\/bitstream\/handle\/10665\/379339\/9789240101531-eng.pdf?sequence=1 [Accessed 15 Jan 2025]."},{"key":"2025072913113118000_10.4.e018220.2","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment, 2022. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240048126 [Accessed 25 Dec 2023]."},{"key":"2025072913113118000_10.4.e018220.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.042"},{"key":"2025072913113118000_10.4.e018220.4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14656566.2021.1967930","article-title":"The pharmacotherapeutic management of pulmonary tuberculosis: an update of the state-of-the-art","volume":"23","author":"Fekadu","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"2025072913113118000_10.4.e018220.5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MCP.0000000000000477","article-title":"Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management","volume":"24","author":"Pontali","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"2025072913113118000_10.4.e018220.6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","article-title":"Management of drug-resistant tuberculosis","volume":"394","author":"Lange","year":"2019","journal-title":"The Lancet"},{"key":"2025072913113118000_10.4.e018220.7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7861\/clinmedicine.19-2-135","article-title":"An update on multidrug-resistant tuberculosis","volume":"19","author":"Park","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"2025072913113118000_10.4.e018220.8","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update, 2022. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240063129 [Accessed 24 Oct 2023]."},{"key":"2025072913113118000_10.4.e018220.9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"2025072913113118000_10.4.e018220.10","unstructured":"World health organization . Tuberculosis profile. 2025. Available: https:\/\/worldhealthorg.shinyapps.io\/tb_profiles\/?_inputs_&group_code=%22global%22&entity_type=%22group%22&lan=%22EN%22 [Accessed 10 Jan 2025]."},{"key":"2025072913113118000_10.4.e018220.11","unstructured":"World Health Organization . Target regimen profiles for tuberculosis treatment, 2023 update, 2023. Available: https:\/\/iris.who.int\/bitstream\/handle\/10665\/373790\/9789240081512-eng.pdf?sequence=1 [Accessed 15 Jan 2024]."},{"key":"2025072913113118000_10.4.e018220.12","unstructured":"World Health Organization . The end tb strategy. 2015. Available: https:\/\/iris.who.int\/bitstream\/handle\/10665\/331326\/WHO-HTM-TB-2015.19-eng.pdf?sequence=1"},{"key":"2025072913113118000_10.4.e018220.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166"},{"key":"2025072913113118000_10.4.e018220.14","doi-asserted-by":"crossref","first-page":"e3563","DOI":"10.1093\/cid\/ciaa1894","article-title":"Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis","volume":"73","author":"Tack","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025072913113118000_10.4.e018220.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2025072913113118000_10.4.e018220.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"2025072913113118000_10.4.e018220.17","unstructured":"World Health Organization . WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update, 2022. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240065116 [Accessed 24 Oct 2023]."},{"key":"2025072913113118000_10.4.e018220.18","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","article-title":"Update of drug-resistant tuberculosis treatment guidelines: A turning point","volume":"130 Suppl 1","author":"Vanino","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2025072913113118000_10.4.e018220.19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"2025072913113118000_10.4.e018220.20","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio884"},{"key":"2025072913113118000_10.4.e018220.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00724-2015"},{"key":"2025072913113118000_10.4.e018220.22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.pulmoe.2021.02.006","article-title":"Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort","volume":"27","author":"Koirala","year":"2021","journal-title":"Pulmonology"},{"key":"2025072913113118000_10.4.e018220.23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12879-022-07693-9","article-title":"Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR\/MDR\/XDR-tuberculosis: a retrospective cohort study in East China","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2025072913113118000_10.4.e018220.24","doi-asserted-by":"publisher","DOI":"10.3201\/eid2505.181823"},{"key":"2025072913113118000_10.4.e018220.25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025072913113118000_10.4.e018220.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"key":"2025072913113118000_10.4.e018220.27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy727"},{"key":"2025072913113118000_10.4.e018220.28","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00544-2018","article-title":"Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa","volume":"51","author":"Olayanju","year":"2018","journal-title":"Eur Respir J"},{"key":"2025072913113118000_10.4.e018220.29","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics12091389","article-title":"The Efficacy and Safety of Bedaquiline in the Treatment of Pulmonary Tuberculosis Patients: A Systematic Review and Meta-Analysis","volume":"12","author":"Tong","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2025072913113118000_10.4.e018220.30","unstructured":"The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance, 2013. Available: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/84879\/9789241505482_eng.pdf;jsessionid=7B9F4400F7E56BE1135DC084406138BA?sequence=1 [Accessed 25 Oct 2023]."},{"key":"2025072913113118000_10.4.e018220.31","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/cid\/ciac176","article-title":"Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs","volume":"75","author":"Huerga","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025072913113118000_10.4.e018220.32","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort","volume":"75","author":"Hewison","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025072913113118000_10.4.e018220.33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12879-021-06666-8","article-title":"Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2025072913113118000_10.4.e018220.34","doi-asserted-by":"crossref","first-page":"100405","DOI":"10.1016\/j.jctube.2023.100405","article-title":"Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis","volume":"34","author":"Ur Rehman","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2025072913113118000_10.4.e018220.35","doi-asserted-by":"crossref","first-page":"106336","DOI":"10.1016\/j.phrs.2022.106336","article-title":"Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysis","volume":"182","author":"Wu","year":"2022","journal-title":"Pharmacol Res"},{"key":"2025072913113118000_10.4.e018220.36","doi-asserted-by":"crossref","DOI":"10.36416\/1806-3756\/e20210384","article-title":"Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"48","author":"Hatami","year":"2022","journal-title":"J Bras Pneumol"},{"key":"2025072913113118000_10.4.e018220.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906"},{"key":"2025072913113118000_10.4.e018220.38","doi-asserted-by":"crossref","unstructured":"Higgins JPT , James Thomas J , Chandler J . Cochrane handbook for systematic reviews of interventions. 2nd edn. Wiley, 2019. Available: https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"key":"2025072913113118000_10.4.e018220.39","doi-asserted-by":"publisher","DOI":"10.1080\/02763869.2019.1588072"},{"key":"2025072913113118000_10.4.e018220.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025072913113118000_10.4.e018220.41","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025072913113118000_10.4.e018220.42","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"2025072913113118000_10.4.e018220.43","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025072913113118000_10.4.e018220.44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025072913113118000_10.4.e018220.45","doi-asserted-by":"crossref","unstructured":"Deeks JJ , Higgins JP , Altman DG , et al . Analysing data and undertaking meta\u2010analyses. Cochrane Handbook for Systematic Reviews of Interventions 2019;241\u201384. doi:10.1002\/9781119536604","DOI":"10.1002\/9781119536604.ch10"},{"key":"2025072913113118000_10.4.e018220.46","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"2025072913113118000_10.4.e018220.47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025072913113118000_10.4.e018220.48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4081\/monaldi.2021.1679","article-title":"Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020","volume":"91","author":"Avaliani","year":"2021","journal-title":"Monaldi Arch Chest Dis"},{"key":"2025072913113118000_10.4.e018220.49","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025072913113118000_10.4.e018220.50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijid.2023.08.001","article-title":"Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study","volume":"135","author":"Fu","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2025072913113118000_10.4.e018220.51","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"2025072913113118000_10.4.e018220.52","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAI.0000000000003150","article-title":"Decentralized, Integrated Treatment of RR\/MDR-TB and HIV Using a Bedaquiline-Based, Short-Course Regimen Is Effective and Associated With Improved HIV Disease Control","volume":"92","author":"Govender","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025072913113118000_10.4.e018220.53","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00811-2"},{"key":"2025072913113118000_10.4.e018220.54","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1023704","article-title":"Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam","volume":"13","author":"Nguyen","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025072913113118000_10.4.e018220.55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang\u2019wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2025072913113118000_10.4.e018220.56","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1093\/cid\/ciac528","article-title":"Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis","volume":"76","author":"Padmapriyadarsini","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025072913113118000_10.4.e018220.57","unstructured":"World Health Organization . Meeting report of the who expert consultation on the definition of extensively drug-resistant tuberculosis. 2021. Available: https:\/\/www.who.int\/publications\/i\/item\/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis"},{"key":"2025072913113118000_10.4.e018220.58","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03300-2020"},{"key":"2025072913113118000_10.4.e018220.59","unstructured":"World Health Organization . Adherence to long-term therapies: evidence for action. 2003. Available: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/42682\/9241545992.pdf"},{"key":"2025072913113118000_10.4.e018220.60","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-1286"},{"key":"2025072913113118000_10.4.e018220.61","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv054"},{"key":"2025072913113118000_10.4.e018220.62","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.10.50"},{"key":"2025072913113118000_10.4.e018220.63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","article-title":"Bedaquiline: Current status and future perspectives","volume":"25","author":"Khoshnood","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2025072913113118000_10.4.e018220.64","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu786"},{"key":"2025072913113118000_10.4.e018220.65","doi-asserted-by":"crossref","DOI":"10.1186\/s40249-021-00819-2","article-title":"Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety","volume":"10","author":"Gao","year":"2021","journal-title":"Infect Dis Poverty"},{"key":"2025072913113118000_10.4.e018220.66","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02208-2018"},{"key":"2025072913113118000_10.4.e018220.67","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2015.03.10"},{"key":"2025072913113118000_10.4.e018220.68","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ejmech.2019.06.068","article-title":"Nitroimidazole-containing compounds and their antibacterial and antitubercular activities","volume":"179","author":"Zhang","year":"2019","journal-title":"Eur J Med Chem"},{"key":"2025072913113118000_10.4.e018220.69","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164571"},{"key":"2025072913113118000_10.4.e018220.70","doi-asserted-by":"crossref","DOI":"10.2147\/DDDT.S281639","article-title":"Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date","volume":"15","author":"Stancil","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2025072913113118000_10.4.e018220.71","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw502"},{"key":"2025072913113118000_10.4.e018220.72","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1164\/rccm.201902-0260LE","article-title":"New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?","volume":"200","author":"Kranzer","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025072913113118000_10.4.e018220.73","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac029","article-title":"Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review","volume":"4","author":"Mallick","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2025072913113118000_10.4.e018220.74","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00639-2023","article-title":"Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"62","author":"Perumal","year":"2023","journal-title":"Eur Respir J"},{"key":"2025072913113118000_10.4.e018220.75","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Microbe"},{"key":"2025072913113118000_10.4.e018220.76","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025072913113118000_10.4.e018220.77","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00002-2"},{"key":"2025072913113118000_10.4.e018220.78","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02919-20","article-title":"Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates","volume":"60","author":"Kaniga","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2025072913113118000_10.4.e018220.79","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s10096-017-3027-3","article-title":"Clinical implication of novel drug resistance-conferring mutations in resistant tuberculosis","volume":"36","author":"Mnyambwa","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2024-018220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:11:51Z","timestamp":1753819911000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2024-018220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":79,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,7]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjgh-2024-018220"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2024-018220","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}